ATE509635T1 - Mittel zur vorbeugung oder heilung entzündlicher darmerkrankungen mit anti-cd81-antikörper als aktivem inhaltsstoff - Google Patents

Mittel zur vorbeugung oder heilung entzündlicher darmerkrankungen mit anti-cd81-antikörper als aktivem inhaltsstoff

Info

Publication number
ATE509635T1
ATE509635T1 AT04772572T AT04772572T ATE509635T1 AT E509635 T1 ATE509635 T1 AT E509635T1 AT 04772572 T AT04772572 T AT 04772572T AT 04772572 T AT04772572 T AT 04772572T AT E509635 T1 ATE509635 T1 AT E509635T1
Authority
AT
Austria
Prior art keywords
preventing
active ingredient
cureing
antibodies
agent
Prior art date
Application number
AT04772572T
Other languages
English (en)
Inventor
Takamasa Watanabe
Kaoru Kikuchi
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE509635T1 publication Critical patent/ATE509635T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
AT04772572T 2003-08-28 2004-08-25 Mittel zur vorbeugung oder heilung entzündlicher darmerkrankungen mit anti-cd81-antikörper als aktivem inhaltsstoff ATE509635T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003304264 2003-08-28
PCT/JP2004/012616 WO2005021792A1 (ja) 2003-08-28 2004-08-25 抗ｃｄ８１抗体を有効成分として含有する炎症性腸疾患の予防または治療剤

Publications (1)

Publication Number Publication Date
ATE509635T1 true ATE509635T1 (de) 2011-06-15

Family

ID=34269264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04772572T ATE509635T1 (de) 2003-08-28 2004-08-25 Mittel zur vorbeugung oder heilung entzündlicher darmerkrankungen mit anti-cd81-antikörper als aktivem inhaltsstoff

Country Status (7)

Country Link
US (1) US20060275289A1 (de)
EP (1) EP1662007B9 (de)
JP (1) JP4749861B2 (de)
AT (1) ATE509635T1 (de)
DK (1) DK1662007T3 (de)
ES (1) ES2363770T3 (de)
WO (1) WO2005021792A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168210A1 (en) * 2007-06-05 2010-07-01 Edwards Iii Carl Keith T-Cell Cytokine-Inducing Surface Molecules and Methods of Use
JP5845171B2 (ja) * 2010-03-04 2016-01-20 大日本住友製薬株式会社 炎症性腸疾患用薬剤
JP6029470B2 (ja) * 2010-12-06 2016-11-24 大日本住友製薬株式会社 ヒトモノクローナル抗体
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423501B2 (en) * 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
ES2334727T3 (es) * 1997-10-06 2010-03-15 Novartis Vaccines And Diagnostics S.R.L. Proteina receptora cd81 de la hepatitis c.
US20030113914A1 (en) * 2001-12-10 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of CD81 expression
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
CN100391469C (zh) * 2000-02-14 2008-06-04 三菱制药株式会社 丙型肝炎治疗药
JP2001299140A (ja) * 2000-04-24 2001-10-30 Sumitomo Pharmaceut Co Ltd Ｈｃｖを増幅しうる細胞及び非ヒト動物
AU2001280608A1 (en) * 2000-07-18 2002-01-30 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
JP3816763B2 (ja) * 2001-06-18 2006-08-30 住友金属パイプエンジ株式会社 管内検査装置及び管内検査方法
JP2003230388A (ja) * 2001-12-05 2003-08-19 Sumitomo Pharmaceut Co Ltd 糖・脂質代謝異常疾患マーカーおよびその利用
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用

Also Published As

Publication number Publication date
EP1662007B9 (de) 2012-02-29
EP1662007A4 (de) 2007-10-31
WO2005021792A1 (ja) 2005-03-10
ES2363770T3 (es) 2011-08-16
JP4749861B2 (ja) 2011-08-17
DK1662007T3 (da) 2011-06-14
EP1662007B1 (de) 2011-05-18
US20060275289A1 (en) 2006-12-07
EP1662007A1 (de) 2006-05-31
JPWO2005021792A1 (ja) 2006-10-26

Similar Documents

Publication Publication Date Title
DK2853272T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
EA200001133A1 (ru) Антипикорнавирусные композиции, их получение и применение
ATE314116T1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
BR0310092A (pt) Combinação de compostos orgânicos
MXPA04000062A (es) Miembros de drenaje extensibles para conectar a tierra la proteccion por interferencia electromagnetica/interferencia por radiofrecuencia.
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
DE69939316D1 (de) Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
ATE310391T1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
DE60144514D1 (de) Verwendung von il-18 inhibitoren
ATE407698T1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE426333T1 (de) Verwendung bestimmter copolymere als adjuvans und mittel fur den agrotechnischen bereich
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE509635T1 (de) Mittel zur vorbeugung oder heilung entzündlicher darmerkrankungen mit anti-cd81-antikörper als aktivem inhaltsstoff
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
EA200500878A1 (ru) Кальцилитические соединения
BRPI0411382A (pt) derivados de 2-aminobenzoil
Jarema et al. Acute and chronic effects of morphine under a progressive-ratio 25 schedule of food delivery
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
FR2873698B1 (fr) Nouveau peptide et composition pharmaceutique le contenant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1662007

Country of ref document: EP